Plain-English translation of NCT05430802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for people with a specific type of lung cancer called non-small cell lung cancer that has an EGFR mutation. You would take a medication called furmonertinib by mouth every day, along with intravenous chemotherapy drugs, for about 3 months before having surgery to remove the cancer. The goal is to shrink the tumor as much as possible before surgery and improve your chances of a good outcome.
Doctors want to know if giving this medication combined with chemotherapy before surgery—rather than after—can help more patients have complete tumor removal and live longer. This approach, called neoadjuvant therapy, may make surgery easier and more effective for people whose lung cancers have this specific genetic mutation.
You would visit the clinic regularly over about 3 months to receive the medication and chemotherapy treatment. You'll take the medication by mouth every day at home, and receive intravenous chemotherapy infusions at the hospital every 3 weeks for a total of 3 treatment cycles. After completing this treatment, you'll have surgery to remove the cancer, followed by monitoring visits to check your recovery and health. Throughout the trial, you'll have blood tests, imaging scans, and check-ups to track how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
China